Patent and commercial terms in negotiation

14 October 2024 Patent and commercial terms in negotiation Blis Technologies Limited (BLIS) advised the market on 24 September 2024 that it had become aware that a key customer, being Bluestone Pharma GmbH (BSP) had filed patents for the BLIS K12™ and BLIS M18™ fermentation processes, containing BLIS’ confidential information that BLIS had shared with a manufacturer, being Austrian company Lactosan GmbH & Co. KG (Lactosan) in prior years under a Non-Disclosure Agreement. Following the announcement of 24 September 2024, BLIS senior executives have been engaged in confidential negotiations with BSP and Lactosan to explore possible settlement options in respect of the alleged contract breaches. BLIS senior executives travelled to Milan, Italy for the week commencing Monday 7th October 2024 to attend the CPHI Milan pharma conference and they also met with BSP and Lactosan representatives individually to continue negotiations. These negotiations are ongoing. No further comment can be made at this stage. Ends For further information, please contact: Scott Johnson CEO +64 21 488 831 About Blis Technologies Ltd Delivering proven health benefits through evidence-based, advanced probiotics Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand and in Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at www.blis.co.nz. Website: www.blis.co.nz Instagram: @blisprobiotics #blisk12 #blism18 #blisq24 Facebook: @BLISProbiotics